Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

APPROVED_FOR_MARKETING

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To provide early access and to evaluate the safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

NCT05321082

Lung Diseases, Interstitial

COMPLETED PHASE3

Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone

NCT02141087

Idiopathic Pulmonary Fibrosis

APPROVED_FOR_MARKETING

Real-life-persistence to Antifibrotic Treatments

NCT06485635

Idiopathic Pulmonary Fibrosis

ACTIVE_NOT_RECRUITING

Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects

NCT03562416

Idiopathic Pulmonary Fibrosis Lung Transplant; Complications

TERMINATED PHASE2

Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)

NCT01979952

Idiopathic Pulmonary Fibrosis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Idiopathic Pulmonary Fibrosis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

nintedanib

soft gelatin capsule

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Signed Informed Consent consistent with ICH-GCP and local laws signed prior to entry into the trial;
2. Male or female patients aged \>=40 years at Visit 1;
3. IPF diagnosis based upon the American Thoracic Society (ATS)/European Respiratory Society (ERS) /Japanese Respiratory Society (JRS)/Latin American Thoracic Society (ALAT) IPF 2011 guideline within 5 years of visit 1;
4. Carbon monoxide diffusing capacity (DLCO)(corrected for Haemoglobin (Hb)): 30%-79% predicted of normal, per institutional standards at the clinic site, at Visit 1;
5. Forced Vital Capacity (FVC) \>= 50% predicted of normal, per institutional standards at the clinic site, at Visit 1.

Exclusion Criteria

1. Eligible to participate or participating in an ongoing actively accruing clinical trial with nintedanib in the treatment of IPF.

Laboratory parameters from Visit 1 must satisfy entry criteria as shown below. Abnormal laboratory parameters may be re-tested if a measurement error is suspected (e.g., there was no abnormal result of this test in the recent history of the patient and there is no related clinical sign). The results of the re-test should be reported within the Screening period (i.e., 28 days of signing the informed consent form).
2. ALT, AST \> 1.5 times upper limit of normal (ULN);
3. Total Bilirubin \> 1.5 times upper limit of normal (ULN);
4. Bleeding risk:

1. patients who require: fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, dabigatran, heparin, hirudin, etc.), or high-dose antiplatelet therapy. Exceptions: prophylactic low dose heparin or heparin flush as needed for maintenance of an indwelling intravenous device (e.g., enoxaparin 4000 IU s.c. per day) and prophylactic use of antiplatelet therapy (e.g., acetylsalicylic acid up to 325 mg/d, or clopidogrel at 75 mg/d, or equivalent doses of other antiplatelet therapy);
2. history of hemorrhagic central nervous system (CNS) event within 12 months of Visit 1;
3. any of the following within 3 months of Visit 1;

* hemoptysis or haematuria
* active gastro-intestinal bleeding or ulcers
* major injury or surgery
4. coagulation parameters:

* international normalised ratio (INR) \> 2
* prothrombin time (PT) and partial thromboplastin time (PTT) \> 150% of institutional upper limit of normal (ULN)
5. Planned major surgery within the next 3 months, including lung transplantation, major abdominal or major intestinal surgery;
6. Thrombotic risk:

1. known inherited predisposition to thrombosis
2. history of thrombotic event (including stroke and transient ischemic attacks) within 12 months of Visit 1;
7. Cardiac disease:

1. Myocardial infarction within 6 months of Visit 1
2. Unstable angina within 1 month of Visit 1;
8. Current or planned usage (during the course of this trial) of any other investigational drug during the course of this trial;
10. Permanent discontinuation of nintedanib within a clinical trial, due to adverse events considered drug-related;
11. Known hypersensitivity to nintedanib or its excipients;
12. A disease or condition which in the opinion of treating physician may put the patient at risk because of participation in this trial or limit the patient's ability to participate in this trial;
13. Alcohol or drug abuse which in the opinion of the treating physician would interfere with participation;
14. Women (of child-bearing potential) who are unwilling to use acceptable methods of contraception;
15. Pregnancy or breast feeding (female patients must have a negative pregnancy test (ß-HCG test in urine or serum) prior to commencing trial treatment).

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No